Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VIGL | US
0.05
1.09%
Healthcare
Biotechnology
31/03/2024
26/07/2024
4.64
4.58
4.75
4.40
Vigil Neuroscience Inc. a clinical-stage biotechnology company focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia the sentinel immune cells of the brain. Its lead candidate is VGL101 a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience Inc. was incorporated in 2020 and is headquartered in Watertown Massachusetts.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
81.2%1 month
105.6%3 months
138.9%6 months
118.2%-
-
1.02
0.13
0.11
-0.17
-
-
-89.06M
174.39M
174.39M
-
-
-
-
-60.18
1.88
17.70
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.21
Range1M
1.21
Range3M
3.59
Rel. volume
0.29
Price X volume
1.62M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Rigel Pharmaceuticals Inc | RIGL | Biotechnology | 10.75 | 188.75M | -1.38% | n/a | -191.02% |
Centrexion Therapeutics Corporation | CNTX | Biotechnology | 2.5 | 187.50M | 2.46% | n/a | 0.00% |
Puma Biotechnology Inc | PBYI | Biotechnology | 3.83 | 184.75M | -2.79% | 11.44 | 217.20% |
MediWound Ltd | MDWD | Biotechnology | 19.8 | 183.81M | 2.22% | n/a | 0.00% |
Fennec Pharmaceuticals Inc | FENC | Biotechnology | 6.51 | 179.86M | -1.51% | 159.75 | 987.03% |
Sangamo Therapeutics Inc | SGMO | Biotechnology | 0.8649 | 179.48M | 28.71% | n/a | 54.35% |
scPharmaceuticals Inc | SCPH | Biotechnology | 4.94 | 178.11M | -0.80% | n/a | 166.09% |
Citius Pharmaceuticals Inc | CTXR | Biotechnology | 0.96 | 173.45M | 3.13% | n/a | 0.47% |
Kodiak Sciences Inc | KOD | Biotechnology | 3.25 | 170.74M | 0.93% | n/a | 73.93% |
INmune Bio Inc | INMB | Biotechnology | 8.58 | 169.73M | 1.30% | n/a | 27.36% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 53.41 | 151.69M | -1.22% | 7.97 | 71.47% |
Saga Communications Inc | SGA | Broadcasting - Radio | 15.09 | 94.51M | 0.73% | 13.08 | 4.17% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.53 | 85.74M | 0.00% | 5.84 | 281.56% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.9816 | 43.11M | -0.96% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 4.16 | 33.56M | 0.24% | n/a | 16.03% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.669 | 20.30M | 4.63% | n/a | 204.50% |
ILAG | ILAG | Building Products & Equipment | 0.8149 | 14.72M | -3.56% | n/a | 5.48% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6489 | 6.18M | 19.99% | n/a | 18.43% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4501 | 5.75M | 0.13% | n/a | 0.00% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.3324 | 5.24M | -0.72% | n/a | 1.80% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.17 | -2.85 | Expensive |
Ent. to Revenue | - | 4,050.30 | - |
PE Ratio | - | 39.84 | - |
Price to Book | 1.02 | 22.96 | Cheaper |
Dividend Yield | - | 1.79 | - |
Std. Deviation (3M) | 138.86 | 75.85 | Riskier |
Debt to Equity | 0.13 | 0.55 | Cheaper |
Debt to Assets | 0.11 | 0.24 | Cheaper |
Market Cap | 174.39M | 3.61B | Emerging |